1.12
price down icon6.67%   -0.08
after-market After Hours: 1.12
loading
Enlivex Therapeutics Ltd stock is traded at $1.12, with a volume of 196.65K. It is down -6.67% in the last 24 hours and up +19.66% over the past month. Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
See More
Previous Close:
$1.20
Open:
$1.18
24h Volume:
196.65K
Relative Volume:
3.04
Market Cap:
$22.90M
Revenue:
-
Net Income/Loss:
$-22.29M
P/E Ratio:
-0.9492
EPS:
-1.18
Net Cash Flow:
$-17.12M
1W Performance:
-3.45%
1M Performance:
+19.66%
6M Performance:
-4.27%
1Y Performance:
-21.13%
1-Day Range:
Value
$1.11
$1.23
1-Week Range:
Value
$1.11
$1.30
52-Week Range:
Value
$0.8101
$1.76

Enlivex Therapeutics Ltd Stock (ENLV) Company Profile

Name
Name
Enlivex Therapeutics Ltd
Name
Phone
-
Name
Address
-
Name
Employee
36
Name
Twitter
@EnlivexT
Name
Next Earnings Date
2024-09-09
Name
Latest SEC Filings
Name
ENLV's Discussions on Twitter

Compare ENLV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ENLV
Enlivex Therapeutics Ltd
1.12 22.90M 0 -22.29M -17.12M -1.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.20 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
525.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
326.09 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
551.22 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
242.07 28.51B 3.81B -644.79M -669.77M -6.24

Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-02-21 Reiterated H.C. Wainwright Buy

Enlivex Therapeutics Ltd Stock (ENLV) Latest News

pulisher
Jun 17, 2025

Sepsis Market Growth to Accelerate in Forecast Period - openPR.com

Jun 17, 2025
pulisher
Jun 13, 2025

Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Jeffersonian

Jun 13, 2025
pulisher
Jun 13, 2025

Trust Consulting Services CEO James Radford Named One of CIO Bulletin's "Best Entrepreneurs to Watch 2025" - Marco Eagle

Jun 13, 2025
pulisher
Jun 13, 2025

Unusual Machines Announces Termination of Definitive Agreement to Acquire Aloft - The Holland Sentinel

Jun 13, 2025
pulisher
Jun 13, 2025

Safe 'N' Sound Environmental Services Ltd. Recognized with 2025 Consumer Choice Award for Asbestos Removal in Halton Region - Sarasota Herald-Tribune

Jun 13, 2025
pulisher
Jun 11, 2025

Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 - IndyStar

Jun 11, 2025
pulisher
Jun 10, 2025

Enlivex Therapeutics (ENLV) to Present Promising Allocetra Data at EULAR Congress | ENLV Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Enlivex Therapeutics to Present Clinical Data of Allocetra in Os - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Enlivex Therapeutics Ltd. to Present Allocetra™ Data at EULAR 2025 Congress in Barcelona - Nasdaq

Jun 10, 2025
pulisher
Jun 10, 2025

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology - The Manila Times

Jun 10, 2025
pulisher
Jun 10, 2025

Breakthrough Cell Therapy Shows Promise in Knee Osteoarthritis: Enlivex Phase I/II Trial Data at EULAR 2025 - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

Interactive Strength Inc. (Nasdaq: TRNR) Updates FAQ's about Increasing 2025 Pro Forma Revenue Guidance to More Than $75M and Other Questions - Reno Gazette Journal

Jun 10, 2025
pulisher
Jun 07, 2025

Millennium Management LLC Acquires New Holdings in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Friday - Defense World

Jun 06, 2025
pulisher
Jun 02, 2025

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform - El Paso Times

Jun 02, 2025
pulisher
May 30, 2025

Enlivex Reports Q1 2025 Financial Results with Reduced Loss - TipRanks

May 30, 2025
pulisher
May 29, 2025

D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering - Lohud

May 29, 2025
pulisher
May 29, 2025

Enlivex Therapeutics (NASDAQ:ENLV) Shares Down 4% – Time to Sell? - Defense World

May 29, 2025
pulisher
May 28, 2025

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program - El Paso Times

May 28, 2025
pulisher
May 21, 2025

ENLIVEX THERAPEUTICS Earnings Preview: Recent $ENLV Insider Trading, Hedge Fund Activity, and More - Nasdaq

May 21, 2025
pulisher
May 20, 2025

Enlivex (ENLV) to Present Cell Therapy Advancements at Israeli B - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Revolutionary Cell Therapy Shows 47% Pain Reduction in Osteoarthritis: Enlivex Reveals Breakthrough Data - Stock Titan

May 20, 2025
pulisher
May 08, 2025

Sheba Medical Center and Enlivex Announce Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers - Barchart.com

May 08, 2025
pulisher
May 07, 2025

Renaissance Technologies LLC Acquires 84,203 Shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) - Defense World

May 07, 2025
pulisher
May 02, 2025

Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis - ACCESS Newswire

May 02, 2025
pulisher
Apr 24, 2025

Enlivex stock holds Buy rating with $7 target from H.C. Wainwright - Investing.com India

Apr 24, 2025
pulisher
Apr 23, 2025

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoa - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Enlivex to Present Allocetra™ Insights at OARSI 2025 - TipRanks

Apr 23, 2025
pulisher
Apr 23, 2025

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World ... - Bluefield Daily Telegraph

Apr 23, 2025
pulisher
Apr 23, 2025

Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress - TradingView

Apr 23, 2025
pulisher
Apr 23, 2025

Game-Changing Cell Therapy Helps Patients Avoid Knee Replacement: Clinical Trial Results Revealed - Stock Titan

Apr 23, 2025
pulisher
Apr 22, 2025

Enlivex enrols all patients in Phase II stage of knee osteoarthritis trial - Yahoo

Apr 22, 2025
pulisher
Apr 22, 2025

Enlivex Therapeutics (NASDAQ:ENLV) Given “Buy” Rating at D. Boral Capital - Defense World

Apr 22, 2025
pulisher
Apr 21, 2025

Enlivex (ENLV) Completes Patient Enrollment for Phase II Allocetra Trial | ENLV Stock News - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Enlivex Completes Phase II Enrollment for Osteoarthritis Trial - TipRanks

Apr 21, 2025
pulisher
Apr 21, 2025

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis - The Manila Times

Apr 21, 2025
pulisher
Apr 21, 2025

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis | ENLV Stock News - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Enlivex Therapeutics Completes Patient Enrollment in Phase II Trial of Allocetra™ for Knee Osteoarthritis - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

Major Milestone: 133-Patient Phase II Trial Completed for Revolutionary Knee Osteoarthritis Treatment Allocetra - Stock Titan

Apr 21, 2025
pulisher
Apr 07, 2025

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth? - Yahoo Finance

Apr 07, 2025
pulisher
Apr 05, 2025

D. Boral Capital Reaffirms “Buy” Rating for Enlivex Therapeutics (NASDAQ:ENLV) - Defense World

Apr 05, 2025
pulisher
Apr 03, 2025

Enlivex Begins Phase I Trial for TMJ Osteoarthritis Treatment - TipRanks

Apr 03, 2025
pulisher
Apr 03, 2025

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - The Manila Times

Apr 03, 2025
pulisher
Apr 03, 2025

Groundbreaking TMJ Treatment Trial Begins: Enlivex Targets Major Medical Need - Stock Titan

Apr 03, 2025
pulisher
Mar 31, 2025

Enlivex Therapeutics Releases 2024 Financial Statements - TipRanks

Mar 31, 2025
pulisher
Mar 27, 2025

HC Wainwright Has Negative Estimate for ENLV FY2025 Earnings - Defense World

Mar 27, 2025
pulisher
Mar 26, 2025

HC Wainwright Forecasts Strong Price Appreciation for Enlivex Therapeutics (NASDAQ:ENLV) Stock - The AM Reporter

Mar 26, 2025

Enlivex Therapeutics Ltd Stock (ENLV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.66
price up icon 0.78%
$36.03
price up icon 0.45%
$21.28
price up icon 3.30%
$100.64
price up icon 1.16%
$106.47
price down icon 0.23%
biotechnology ONC
$242.07
price up icon 0.36%
Cap:     |  Volume (24h):